1. Field, M. J. & Boat, T. F. (eds). Rare Diseases and Orphan Products: Accelerating Research and Development (The National Academies Press, Washington DC, 2011).
2. Tambuyzer, E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nature Rev. Drug Discov. 9, 921–929 (2010).
3. Philippidis, A. Orphan drugs, big pharma. Hum. Gene Ther. 22, 1037–1040 (2011).
4. Hyde, R. & Dobrovolny, D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? American Health and Drug Benefits 3, 15–23 (2010).